CDE Approves RinuaGene’s mRNA-Based RG002 for Clinical Study in Cervical Dysplasia
China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has indicated...
RinuaGene
RinuaGene Receives US FDA IND Approval for HPV-Associated Tumor mRNA Vaccine RG002
RinuaGene, a leading mRNA specialist headquartered in Suzhou, has announced that it has received Investigational...
RinuaGene Raises $14.4M in Pre-Series A+ for mRNA Drug Development
RinuaGene, an mRNA-based drug developer based in Suzhou, has reportedly raised close to RMB 100...